-
Rogers Corporation names Armand Lauzon as new board chair
-
Genentech launches direct-to-patient program for flu drug Xofluza
-
Genentech breaks ground on $700 million manufacturing facility in North Carolina
-
Starboard Value Builds Over 9% Stake In Rogers Corp (ROG) - WSJ
-
Rogers (ROG) Misses Q2 EPS by 16c; offers guidance
-
FDA rejects Genentech's Columvi combination for lymphoma treatment
-
Rogers Corporation names interim CEO as Colin Gouveia exits
-
Rogers (ROG) Halted, News Pending
-
Roche's (RHHBY) Genentech presents results from Phase 3 study of Lunsumio
-
Roche (RHHBY) to invest $550 million for manufacturing hub expansion
-
Rogers (ROG) Reports In-Line Q1 EPS, provides guidance
-
HSBC cuts biotech stocks: Eli Lilly lowered to Reduce
-
Pharma stocks slide after Trump signals tariffs on sector
-
BofA: 'Oil valuations still have room to fall', 'we believe that tier 1 oil-levered E&P’s are discounting $60 WTI / 10% discount rate'
-
Quest Diagnostics (DGX) Introduces HPV Specimen Self-Collection for Cervical Cancer Screening
-
Rogers (ROG) Misses Q4 EPS by 38c ; Offers Guidance
-
FDA Approves Genentech’s Susvimo as Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
-
Rogers (ROG) Appoints Woon Keat Moh to its Board
-
Rogers (ROG) Appoints Laura Russell as Chief Financial Officer
-
Rogers (ROG) Tops Q3 EPS by 13c, Misses on Revenue; Offers Q4 Guidance
-
B.Riley Reiterates Buy Rating on Rogers Corp (ROG)
-
Rogers (ROG) Announces Departure of Chief Financial Officer
-
Rogers (ROG) Tops Q2 EPS by 9c, provides guidance
-
Genentech’s Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term Diabetic Macular Edema (DME) Study

